Summit Therapeutics (NASDAQ:SMMT) stock rose 5% on Thursday while AstraZeneca (NASDAQ:AZN) shares fell 2% following a Bloomberg report that the companies are in discussions for a potential $15 billion ...

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin ...

BioVersys & Shionogi ink global research collaboration for broad-spectrum NTM clinical candidate: Basel, Switzerland Thursday, July 3, 2025, 10:00 Hrs [IST] BioVersys AG, a multi- ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Swiss biopharma company BioVersys (today announced a research and exclusive license option agreement with the Japanese ...

Basel-based BioVersys stands to receive CHF 5 million upfront under the terms of the deal, which could be worth up to CHF 479 ...

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to ...

Viral proteases, the key enzymes that regulate viral replication and assembly, are promising targets for antiviral drug discovery. Herpesvirus proteases are enzymes with no crystallographically ...

More than 65 new companies debut on the FleetOwner 500: Private, which ranks the biggest American transportation organizations for non-trucking companies.

At 3:30 p.m. on the Upper East Side of New York City, Emma and Maddie, both 12 years old, are sipping matcha lattes at their usual after-school hangout: Blank Street Coffee. As the name suggests ...

Stock Market News, June 18, 2025: Dow ends modestly lower, S&P 500 flat and Nasdaq edges up as Fed holds rates steady but forecasts higher inflation and lower growth Investors react to the Fed's ...